Epigenomic plasticity enables human pancreatic α to β cell reprogramming

Nuria C. Bramswig,1 Logan J. Everett,1 Jonathan Schug,1 Craig Dorrell,2 Chengyang Liu,3 Yanping Luo,3 Philip R. Streeter,2 Ali Naji,3 Markus Grompe,2 and Klaus H. Kaestner1

1Department of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2Oregon Health and Science University, Portland, Oregon, USA. 3Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Insulin-secreting β cells and glucagon-secreting α cells maintain physiological blood glucose levels, and their malfunction drives diabetes development. Using ChIP sequencing and RNA sequencing analysis, we determined the epigenetic and transcriptional landscape of human pancreatic α, β, and exocrine cells. We found that, compared with exocrine and β cells, differentiated α cells exhibited many more genes bivalently marked by the activating H3K4me3 and repressing H3K27me3 histone modifications. This was particularly true for β cell signature genes involved in transcriptional regulation. Remarkably, thousands of these genes were in a monovalent state in β cells, carrying only the activating or repressing mark. Our epigenomic findings suggested that α to β cell reprogramming could be promoted by manipulating the histone methylation signature of human pancreatic islets. Indeed, we show that treatment of cultured pancreatic islets with a histone methyltransferase inhibitor leads to colocalization of both glucagon and insulin and glucagon and insulin promoter factor 1 (PDX1) in human islets and colocalization of both glucagon and insulin in mouse islets. Thus, mammalian pancreatic islet cells display cell-type–specific epigenomic plasticity, suggesting that epigenomic manipulation could provide a path to cell reprogramming and novel cell replacement-based therapies for diabetes.

Introduction
The islets of Langerhans, miniature endocrine organs within the pancreas, are essential regulators of blood glucose homeostasis and play a key role in the pathogenesis of diabetes, a group of diseases currently affecting more than 336 million people worldwide, with healthcare costs by diabetes and its complications of up to $612 million per day in the US alone (1). While for decades, insulin deficiency was considered the sole issue, recent studies emphasize excess glucagon as an important part of diabetes etiology, making diabetes a “bihormonal disease” (2). Increasing the number of insulin-producing β cells while decreasing the number of glucagon-producing α cells, either in vitro in donor pancreatic islets before transplantation into type 1 diabetics or in vivo in type 2 diabetics, is a promising therapeutic avenue.

Epigenetic studies have shown that manipulation of rodent histone acetylation signatures can alter embryonic pancreatic differentiation and composition (3, 4). Recently, studies in rodent models have suggested that under extreme conditions, such as enforced paired box gene 4 (Pax4) or pancreatic and duodenal homeobox gene 1 (Pdx1) overexpression or near complete β cell ablation, cells can be reprogrammed toward the β cell fate (5–7). However, the molecular basis of this reprogramming potential is unknown. We wondered whether epigenetic mechanisms play a role in this process and whether α cells exist in a metastable epigenetic state that facilitates their reprogramming. While previous studies have characterized histone methylation signatures, open chromatin sites, and CTCF-binding (CCCTC-binding factor) sites of whole human islets (8–10), cell-type–specific epigenetic signatures and RNA sequencing (RNA-Seq) analysis of human pancreatic cells have not been determined.

We employed a previously published sorting strategy of human pancreatic α, β, and exocrine (duct and acinar) cells (11) to assess their cell-type–specific histone methylation profiles. We chose to investigate the trimethylation of the fourth amino acid (lysine) on histone H3 (H3K4me3) and the H3K27me3 mark because of their known association with cell-fate determination and important roles in the regulation of transcription (12–14). The presence of both marks at the same gene is referred to as a bivalent mark and is more common in pluripotent, undifferentiated cells than in terminally differentiated cells (12). The bivalent mark keeps genes poised in an activatable state and is usually resolved during differentiation.

Our human pancreatic cell-type–specific analysis of the activating and repressive histone methylation landscape and the parallel determination of the complete transcriptome using RNA-Seq provide an important resource for the diabetes research community. Importantly, detailed analysis of these histone marks, their integration with gene expression data, and in vitro manipulation of their epigenomic signature suggests a new pathway to reprogram α to β cells.

Results
Human pancreatic islets from deceased organ donors (n = 6, Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI66514) were sorted into highly enriched α, β, and exocrine (duct and acinar) cell fractions using a recently developed cell-surface antibody panel (11) and the additional antibody 2D12 (Figure 1A). Sample purity of the sorted α and β cell populations was validated by quantitative RT-PCR (qRT-PCR) for relevant marker genes. We calculated the sample purity as percent.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(3):1275–1284. doi:10.1172/JCI66514.
Figure 1
Study design for determination of the transcriptome and differential histone marks in sorted human islet cells. (A) Human islets were dispersed and subjected to FACS to obtain cell populations highly enriched for α, β, and exocrine (duct and acinar) cells. Chromatin was prepared and precipitated with antibodies for H3K4me3 and H3K27me3 followed by high-throughput sequencing (ChIP-Seq) (H3K4me3: n = 4 α, n = 4 β, n = 2 exocrine, H3K27me3: n = 3 α, n = 3 β, n = 2 exocrine). RNA-Seq analysis was performed to determine mRNA and lncRNA levels (n = 3 α, n = 3 β, n = 2 exocrine). (B) Sample purity assessment. Normalized insulin and glucagon expression levels of the individual α, β, and 2–13.1% contamination in the β cell populations, and exocrine cells are shown in Figure 1D. Islets were dispersed and subjected to FACS to obtain cell populations highly enriched for α, β, and exocrine cells. Chromatin was prepared and precipitated with antibodies for H3K4me3 and H3K27me3 followed by high-throughput sequencing (ChIP-Seq) (H3K4me3: GLITR; H3K27me3: STAR) on individual replicates, followed by signal pooling, was employed to assess histone modification profiles of α, β, and exocrine cells. Heat map analysis confirmed reproducibility of replicates. (D) Genome browser image of the PDX1 locus showing H3K4me3 enrichment in β, and exocrine cells and H3K27me3 enrichment only in α cells (defined as monovalent H3K4me3 enrichment in β, and exocrine cells, bivalent mark in α cells; CpG islands: red bars).

Figure 2
Analysis pipeline for H3K4me3 and H3K27me3 profiles. (A) Human islets were dispersed and subjected to FACS to obtain cell populations highly enriched for α, β, and exocrine (duct and acinar) cells. Chromatin was prepared and precipitated with antibodies for H3K4me3 and H3K27me3 followed by high-throughput sequencing (ChIP-Seq) (H3K4me3: n = 4 α, n = 4 β, n = 2 exocrine, H3K27me3: n = 3 α, n = 3 β, n = 2 exocrine). RNA-Seq analysis was performed to determine mRNA and lncRNA levels (n = 3 α, n = 3 β, n = 2 exocrine). (B) Sample purity assessment. Normalized insulin and glucagon expression levels of the individual α, β, and 2–13.1% contamination in the β cell populations, and exocrine cells are shown in Figure 1D. Chromatin was prepared and precipitated with antibodies for H3K4me3 and H3K27me3 followed by high-throughput sequencing (ChIP-Seq) (H3K4me3: GLITR; H3K27me3: STAR) on individual replicates, followed by signal pooling, was employed to assess histone modification profiles of α, β, and exocrine cells. Heat map analysis confirmed reproducibility of replicates. (D) Genome browser image of the PDX1 locus showing H3K4me3 enrichment in β, and exocrine cells and H3K27me3 enrichment only in α cells (defined as monovalent H3K4me3 enrichment in β, and exocrine cells, bivalent mark in α cells; CpG islands: red bars).
In addition, jagged 1 (JAG1), the transcription factor SOX9, and pancreas-specific transcription factor 1a (PTF1A) are also among the exocrine-specific genes. Our RNA-Seq based list of β cell–enriched genes includes the β cell–specific transcription factors MAFA, NKX6-1, and PDX1 as well as the β cell hormone insulin (INS) and one of the key enzymes for its synthesis, prohormone convertase 1 (PCS1). The β cell–specific cluster also included histone deacetylase 9 (HDAC9), which has previously been shown to be enriched in murine β cells (4). Remarkably, we found many genes identified in genome-wide association studies for nonautoimmune forms of diabetes (17) among the α cell and β cell–specific genes, such as the hepatocyte nuclear transcription factor 1-α (HNF1A) and the protein-tyrosine phosphatase δ (PTPRD) in α cells, the potassium channels KCNQ2 and KCNJ11, and the zinc transporter SLC30A8 in β cells. The complete gene lists of α, β, and exocrine cell–specific genes are provided in Supplemental Table 2.

In addition, we provide the transcriptomes of our α, β, and exocrine cell populations, including normalized expression values of every gene (Supplemental Table 3).

To extend the analysis of our human α and β cell–specific transcription atlas, we searched for novel, cell-type–specific long noncoding transcripts. Long noncoding RNA molecules (lncRNAs) have been implicated as important developmental regulators, cell lineage allocators, and contributors to disease development (18). Recently described human islet lncRNAs were regulated during development and dysregulated in type 2 diabetic islets (19). Therefore, discovery of novel lncRNAs and evaluation of their function can potentially provide insight into diabetes pathogenesis. We discovered 12 β cell–specific, and 5 α cell–specific noncoding transcripts, indicative of the valuable research resource represented by our transcriptome data (Supplemental Table 4).

Next, we focused on the genome-wide, monovalent histone modification landscapes of our sorted pancreatic cell populations. We identified monovalent H3K4me3-enriched regions in α, β, and exocrine cells and compared them among the 3 cell types (Figure 3A). Strikingly, the vast majority of monovalently H3K4me3-marked genes were shared among the 3 pancreatic cell lineages (83%–95%), reflecting both their related function in protein secretion and common embryonic descent (Figure 3A).

To investigate the landscape of repressive histone modifications, we performed H3K27me3 ChIP-Seq analysis and detected monovalent H3K27me3 enrichment at 3,755 gene regions in α, 4,420 gene regions in β, and 5,628 gene regions in exocrine cells (Figure 3B). Similar to the H3K4me3 modification, we found a high degree of overlap of monovalently H3K4me3-marked genes among the 3 cell populations (73%–83%, Figure 3B). Our H3K4me3 and H3K27me3 enrichment calls were validated by heat map analysis of the biological α and β cell replicates showing low interindividual variability (Figure 3, C and D). The box-and-whisker plots display the gene expression levels of bivalently marked, H3K4me3 marked, H3K27me3 marked and “unmarked” genes in each cell population (Figure 3, E–G). We show that bivalent, monovalent H3K4me3, and monovalent H3K27me3
enrichment calls were correlated genome wide with their respective mRNA levels at high statistical significance.

Bernstein and colleagues observed bivalent marks to be common in undifferentiated cells, such as ES cells and pluripotent progenitor cells, and in most cases, one of the histone modification marks was lost during differentiation, accompanying lineage specification (12–14). Consequently, most genes in differentiated cells are marked by either H3K4me3 or H3K27me3, corresponding to an expressed or repressed state, respectively. Preserving the bivalent state in a subset of genes was suggested to maintain higher plasticity (12–14). Interestingly, α cells showed the highest incidence of bivalent marks (2915 gene regions), followed by β cells (1914) and exocrine cells (1368) (Figure 4). As an internally controlled data set, we determined the bivalent domains for all 3 cell types in 1 individual donor (CITH068) and confirmed the higher number of bivalent marks in α cells (Supplemental Figure 1).
Analysis of genes carrying a bivalent mark in β cells showed that the majority of these genes were also marked bivalently in α cells (1,474 genes, 77%), while 26 genes carried a monovalent H3K27me3 mark and 406 genes carried a monovalent H3K4me3 mark in α cells. Gene ontology analysis (20, 21) of the 406 genes marked bivalently in β cells, but monovalently by H3K4me3 in α cells, revealed 3 significantly enriched categories (Figure 4B). However, no significantly enriched categories were identified in the 523 genes marked bivalently in exocrine, but monovalently by H3K4me3 in β cells, or the 467 genes marked bivalently in exocrine, but monovalently by H3K4me3 in α cells (data not shown). The histone methylation status (H3K4me3, H3K27me3, bivalent, none of the above) of every gene in α, β, and exocrine cells is provided in Supplemental Table 5.

Interestingly, nearly half of the genes that displayed a bivalent mark in α cells were marked only by H3K4me3 or H3K27me3 in β cells (48%, 1,406 genes) (Figure 4A) in contrast to 434 genes (22%) marked bivalently in β cells, but monovalently in α cells. Strikingly, gene ontology analysis of genes that were marked bivalently in α cells, but only by the repressive H3K27me3 mark in β cells, displayed highly significant enrichment for genes involved in developmental processes (Figure 4C and Supplemental Table 6), suggesting a more plastic epigenetic state of developmental genes in α cells and a more fixed epigenetic condition in β cells. To further strengthen these observations, we compared transcriptional regulators marked bivalently in human ES cells (hESCs) (22) to their histone profile in α and β cells. We found that only 26% of all transcriptional regulators marked bivalently in hESCs also showed a bivalent mark in β cells, while nearly half of them were marked bivalently in α cells (44%) (Figure 4D). Further analysis of genes marked bivalently in both hESCs and α cells showed that 43% of these genes were H3K27me3 modified in β cells (Figure 4D). These findings provide additional support for the enhanced epigenetic plasticity of human α cells.

Next, we integrated our histone modification ChIP-seq data sets with the specific transcriptional signatures of α, β, and exocrine cells identified from our RNA-seq analysis (Figure 2B). Quantitative analysis of H3K4me3 and H3K27me3 enrichment at the specific transcriptional signatures of human α and β cells reveals a higher overlap between α cells and hESCs (44%, right pie chart) than between β cells and hESC (26%, left pie chart). Many of the genes marked bivalently both in α cells and hESCs carry the repressive mark in β cells (43%, dark blue portion of inset).

Figure 4
Human α cells demonstrate a higher number of bivalently marked genes than β and exocrine cells. (A) Here, α cells display more bivalently marked loci than β and exocrine cells. Nearly half of the genes bivalently marked in α cells carry a monovalent mark in β cells (purple and dark blue portion of the far left bar corresponding to H3K4me3 and H3K27me3 marks in β cells, respectively). (B) 406 genes are marked bivalently in β cells, but monovalently by H3K4me3 in α cells, and gene ontology analysis for these genes shows 3 modestly enriched categories: regulation of RNA metabolic process, regulation of transcription, and transcription. (C) Genes marked bivalently in α cells, but monovalently by H3K27me3 in β cells, are significantly enriched for developmental processes. For detailed GO analysis see Supplemental Table 6. (D) Comparison of transcriptional regulators marked bivalently in hESCs (22) to the histone modification signatures of human α and β cells reveals a higher overlap between α cells and hESCs (44%, right pie chart) than between β cells and hESC (26%, left pie chart). Many of the genes marked bivalently both in α cells and hESCs carry the repressive mark in β cells (43%, dark blue portion of inset).
Finally, we focused our cell-type–specific analysis of the histone modification landscape on α and β cell-specific genes known to be important for pancreatic development and endocrine cell function. Analysis of the histone marks of α cell–specific genes in β cells identified many as being marked monovalently by H3K4me3 (HNF1A, PCSK2) or by H3K27me3 (Iroquois related homeobox 2 [IRX2], GCG, IRX1, ARX), whereas only 2 genes showed a bivalent histone modification profile (DPP4, PTPRD) (Figure 5B). As expected, most α cell–specific genes were marked monovalently by H3K4me3 in β cells. However, the genes PTPRD, IRX1, and the locus encoding the α cell–specific transcription factor ARX were marked bivalently (Figure 5B). Strikingly, most β cell–specific genes important for β cell function displayed monovalent H3K4me3 enrichment (with the exception of HDAC9) in β cells (Figure 5C), while 7 of...
Figure 6
Inhibition of histone methyltransferases leads to partial endocrine cell-fate conversion. (A) H3K27me3 ChIP-Seq analysis of human islets shows decreased H3K27me3 levels at the ARX, MAFA, and PDX1 loci following treatment of human islets with the histone methyltransferase inhibitor Adox. (B) Adox-treatment of human islets results in colocalization of glucagon (red) and insulin (green) granules within the same cell (yellow arrows), suggesting partial endocrine cell fate conversion, which was not seen in vehicle-treated islets (control). Original magnification, ×63. For Z-stack confocal images see Supplemental Videos 1 and 2. (C) Treatment of human islets with Adox results in colocalization of the β cell–specific transcription factor Pdx1 (white) and glucagon (red), further indicating endocrine reprogramming (white arrows: glucagon-positive, Pdx1-negative cells; yellow arrows: glucagon-positive, Pdx1-positive cells). The images on the right correspond to the area within yellow box. Original magnification, ×63. (D) Quantification of glucagon-positive, Pdx1-positive cells in untreated and Adox-treated human islets reveals many double-positive cells after Adox treatment, indicating initiation of reprogramming events in α cells. (E) Adox treatment of human islets leads to a decrease in NKX6-1 and MAFA levels in β cells (n = 3 α, n = 3 β, n = 2 treated α, n = 2 treated β), an increase in PDX1-levels, and no change in INS and GCG levels. (F) In Adox-treated α cells, we observe no change in INS and GCG expression, a slight decrease in NKX6-1 and MAFA levels, and an increase of ARX and PDX1 expression.
12 β cell–specific loci were marked bivalently in α cells, including the functionally relevant genes PCSK1 and GLP1R and the genes encoding the crucial β cell–specific transcription factors MAFA and PDX1. We extended our findings by utilizing previously published H3K4me3 and H3K27me3 data of CD4-positive T cells (23) and compared our pancreatic histone modification profiles to the histone modification landscape of this extrapancreatic cell type. The histone modification profiles of all strongly α, β, and exocrine cell–specific genes in α, β, exocrine, and CD4+ T cells can be found in Supplemental Table 7. As expected, we found significant monovalent enrichment for the activating H3K4me3 mark in only 4 of the 34 selected α, β, and exocrine cell–specific genes (Supplemental Table 8), as these pancreatic genes are not active in lymphoid cells. In summary, α cells preserve high bivalency in many genes known to be crucial for endocrine cell development and function.

The high incidence of bivalent marks in α cells, the interesting bivalent pattern of β and α cell–specific transcription factors in α cells, and the large overlap with bivalently marked transcriptional regulators in hESCs raised the possibility that epigenomic manipulations could be exploited to reprogram human α cells toward the β cell phenotype. Several drugs, such as adenosine dialdehyde (Adox) and 3-deazaneplanocin A (DZNep), interfere with histone methylation (24). We employed the general histone methyltransferase inhibitor Adox, which among others decreases H3K27me3 levels (24), to test whether modulation of the histone methylation status of human pancreatic islets could promote reprogramming. To validate the effectiveness of the histone methyltransferase inhibitor Adox in human islet tissue, we investigated the H3K27me3 modification landscape after Adox treatment. The small numbers of cells recovered after Adox-treatment and FACS analysis did not allow us to perform cell-type–specific analysis of the H3K27me3 profiles, so we compared the H3K27me3 profiles of whole human islets cultured in the absence or presence of Adox. This experiment allowed us to assess whether H3K27me3 levels of repressed genes are decreased after Adox treatment. Indeed, analysis of genes that carry a bivalent mark or a monovalent H3K27me3 mark in all pancreatic cell populations displayed a strong decrease in H3K27me3 enrichment after Adox treatment (Supplemental Figure 3A). In addition, this experiment approximated a cell-type–specific analysis of the H3K27me3 profiles of a subset of β cell–specific pancreatic transcription factors, namely those which are marked bivalently in α cells, but monovalently by H3K4me3 in β cells (MAFA and PDX1). Since α and β cells compose the vast majority (approximately 90%) of the human islet (25) and exocrine cells do not survive in culture (26), any change in H3K27me3 enrichment levels at these loci is thus likely indicative of changes in α cells at the MAFA and PDX1 loci, as there is no H3K27me3 present at these genes in β cells to begin with. In addition, we investigated the H3K27me3 profile of the α cell–specific transcription factor ARX, which is marked bivalently in β cells, but monovalently by H3K27me3 in β cells. Our H3K27me3 ChiP-Seq analysis confirmed the expected decrease of H3K27me3 enrichment at these 3 gene loci after Adox treatment (Figure 6A).

Strikingly, we found that treatment of human islets with Adox resulted in the occasional cooccurrence of glucagon and insulin granules within the same islet cell, which was not observed in untreated islets (Figure 6B, Supplemental Videos 1 and 2, and Supplemental Figure 3B). A priori, the colocalization of glucagon with insulin could be due to α to β cell fate or β to α cell fate conversion. As lineage tracing is not possible in human samples, we next employed a murine genetic lineage tracing model to assess the origin of the dual hormone–positive cells. For this purpose, we treated islets from Glucagon-Cre; Rosa26EYFP mice, in which α cells are permanently marked by yellow fluorescence protein (YFP) expression (27, 28) with Adox in vitro. Adox-treated islets showed insulin granules in YFP+ cells, which were not observed in untreated control islets (Supplemental Figure 3, C and D), supporting partial conversion of α cells to the β cell fate. Unfortunately, at the present time, no inducible Glucagon-Cre ER line exists, and the possibility that Adox-treated β cells activated the Glucagon-Cre promoter cannot be excluded. Since the colocalization of glucagon and insulin granules was observed in a small number of cells, we wanted to investigate whether the important β cell marker PDX1 was present in glucagon-positive cells, indicating the initiation of partial reprogramming events. Strikingly, we found that Adox treatment caused nuclear PDX1 expression in many glucagon-positive cells (Figure 6, C and D).

To investigate the transcriptional changes in Adox-treated human islets and confirm increased PDX1 expression, we performed FACS analysis after Adox treatment using the same antibody panel as described above, followed by RNA-Seq analysis (n = 2 treated α, n = 2 treated β, technical replicates) and focused on cell-type–specific hormones and transcription factors. To assess whether Adox-treated β cells become more α cell like or vice versa, we first compared the ratio of expression levels in untreated β cells and untreated α cells (β/α) to the ratio in Adox-treated β cells and untreated α cells (Adox-β/α) (Figure 6E). We found a decrease in NKKX6-1 and MAFA levels, an increase in PDX1 levels, and no change in insulin expression, but observed no change in the expression levels of the α cell–specific genes glucagon or ARX, giving no indication for a gain of α cell identity. Second, we compared the ratio of expression values in untreated α cells and untreated β cells (α/β) to the ratio in Adox-treated α cells and untreated β cells (Adox-α/β) to elucidate whether Adox-treated α cells become more “β cell like” (Figure 6F). Our analysis revealed no change in insulin and glucagon and an increase in ARX levels. Interestingly, we detected a slight decrease in NKKX6-1 and MAFA levels, but an increase in PDX1 expression. Taken together, these results confirm our observations of PDX1 expression in glucagon-positive cells in the immunofluorescent staining and favor partial α to β cell fate conversion over the alternative.

Discussion

Epigenetic modifications play important roles in the differentiation and functional maintenance of cell types and contribute to the development of complex diseases (29). Therefore, it is crucial to determine the specific epigenomic and transcriptional landscape of disease-relevant cell types and understand the epigenetic mechanisms involved in maintaining or converting their cell-type–specific identity. Previous studies have shown that reprogramming of α cells toward the β cell fate can occur under extreme conditions in mice (5–7). Using ChiP-Seq and RNA-Seq analysis, we investigate the cell-type–specific, genome-wide H3K4me3 and H3K27me3 profiles and transcriptional landscapes of human α and β cells, determined cell-type–specific differences, and showed that there is an epigenomic basis for this reprogramming potential.

Our transcriptome analysis reveals clusters of α, β, and exocrine cell–specific genes and determines genes that were associated with an increased risk for nonautoimmune forms of diabetes in genome-wide association studies among α and β cell–specific genes, which stresses the relevance of α and β cells in diabetes
development. HDAC9 is also among our human cell–specific genes (Figure 2B). Lenoir and colleagues observed β cell–specific expression of the histone deacetylase 9 (Hdac9) in mice and detected an increase in β cell mass in Hdac9+/- mice (4). It would be interesting to investigate whether HDAC9 inhibitors might show a similar effect in human islets and whether HDAC9 could be a target for diabetes treatment.

We show that human α, β, and exocrine cells share very similar monovalent H3K4me3 and H3K27me3 histone modification maps. This does not support previously published murine H3K4me3 modification profiles, in which β clusters with neural tissues, but not acinar cells (30). This discrepancy might be due to the different experimental setup. While van Arensbergen and colleagues investigated the H3K4me3 profiles using promoter arrays with limited coverage and sensitivity (30), we performed genome-wide H3K4me3 ChIP-Seq analysis and therefore analyzed a larger number of genes.

We discovered that pancreatic α cells carry hundreds of bivalent marks on developmental regulatory genes and display a bivalent modification profile remarkably similar to that of hESC, suggesting a more plastic epigenomic state for α cells than for β and exocrine cells. Importantly, many β cell–specific signature genes involved in gene regulation are bivalently marked in α cells. Therefore, we propose that this plastic epigenomic state of the α cell explains in part the relative ease with which α cells have been reprogrammed toward the β cell fate in various mouse models (5–7). In contrast, exocrine cells display the smallest number of bivalent marks (Figure 4A), which could explain the necessity of enforced expression of multiple key transcription factors to achieve limited conversion of exocrine cells toward the β cell fate in vivo (31).

Remarkably, we found that simple treatment of islets with the unspecific histone methyltransferase inhibitor Adox results in partial reprogramming of endocrine cell fates. After Adox treatment, we showed colocalization of insulin and glucagon in a small number of cells, but coexpression of the β cell marker PDX1 and glucagon at a much higher frequency. The discrepancy between the low number of GCG+INS+ and the much higher number of GCG+PDX1+ cells suggests that reprogramming was initiated in a substantial subpopulation of α cells, but was nearly completed in only a few. As discussed below, the explanation for this incomplete reprogramming might be provided in our RNA-Seq analysis of Adox-treated α and β cells.

Although the colocalization of INS or PDX1 and GCG could a priori be due to β to α cell or α to β cell fate conversion, there are multiple lines of evidence indicating that it is caused by partial reprogramming of α to β cell fate: (a) the higher genome-wide bivalency of α cells, especially at developmental regulatory genes and transcriptional regulatory genes expressed specifically in β cells, (b) the high overlap of bivalently marked transcriptional regulators of cells with hESC, (c) the fact that 2 of the 3 β cell–specific transcription factors are marked bivalently (PDX1 and MAFA) in α cells, (d) the colocalization of insulin in lineage-labeled α cells of GlucagonCre; Rosa26EYFP mice, and (e) the expression patterns in Adox-treated α and β cells, which we will discuss in more detail below.

Our expression analysis of α and β cell–specific hormones and transcription factors following Adox treatment supports partial α to β cell conversion, provides evidence for the limited specificity of Adox, and explains the incomplete conversion of the α to β cell fate. For example, although NXX6-1 is monovalently marked by H3K4me3 in α and β cells and therefore should not be affected by Adox treatment, its expression is decreased in Adox-treated α and β cells. This is likely due to the unspecific nature of the histone methyltransferase inhibitors currently available (24). In addition, MAFA, a bivalently marked gene in α cells, is not induced and maintains extremely low mRNA levels after Adox treatment. The persistently low expression of NKK6-1 and MAFA, and possibly the increased expression of ARX in Adox-treated α cells, likely contributes to the incomplete reprogramming of α to β cells. In fact, Zhou and colleagues showed that enforced expression of Neurog3, Pdx1, and Mafa is necessary to achieve reprogramming of adult exocrine cells to β-like cells in mice (31), which stresses the requirement of Mafa expression for the accrual of partial β cell identity. Importantly, the consistently low ARX expression in Adox-treated β cells and the increased PDX1 expression in treated α cells strongly supports the switch from α to β cell fate, and not vice versa. Given the limited specificity of currently available “epigenomic drugs,” and the absence of cell division in cultured islets, the fate conversion achieved was only partial. Nevertheless, our findings suggest that a more targeted manipulation of the histone methylation signature in a histone modification and gene-specific manner might be exploited to promote a more complete human α to β cell fate conversion.

In summary, our cell-type–specific study of histone modification signatures and corresponding RNA-Seq–based transcriptomes provides a valuable resource for the diabetes research community. Our results establish human cell-type–specific epigenomic plasticity and suggest that epigenomic manipulation of fully differentiated human islet cells provides a path to cell reprogramming, which could be exploited for in vitro differentiation protocols toward the β cell fate and cell replacement–based therapy for diabetes.

Methods

FACS sorting of human islet cells and experimental setup. We performed FACS sorting on dispersed human islets using cell surface antibodies (1:20) and secondary antibodies (1:200; 115-116-075, 115-135-164, Jackson Immunoresearch) as described before (11) to obtain cell populations highly enriched for α, β, and exocrine (duct and acinar) cells. Total RNA was isolated from whole islets, and sorted α, β, and exocrine cells using the Ambion mirVana miRNA Isolation Kit (AM1560) reverse transcribed to cDNA using SuperScript II reverse transcriptase (Invitrogen) and mRNA levels (normalized to β-actin, GAPDH) were measured by qPCR analysis. Sample purity of the sorted α and β cell populations was calculated as percentage of contamination by the opposite cell type. The formula can be found in the Supplemental Methods. In addition, chromatin was prepared from all sorted cell populations (see below).

ChIP-Seq analysis. ChIP and preparation of ChIP-Seq libraries was performed on individual cell sorts for each cell type and donor (H3K4me3: 8580, Abcam; H3K27me3: 07-449, Upstate). A detailed protocol including chromatin preparation, ChIP, and sequencing library preparation (option 1: nonmultiplexed or option 2: multiplexed) is provided in Supplemental Methods.

Computational analysis. We utilized the GLITR algorithm (32) for detection of H3K4me3 enrichment and the STAR algorithm (33) for detection of H3K27me3 enrichment, as the broad architecture of the repressive H3K27me3 mark requires more sensitive peak-calling algorithms for precise analysis (34). All computational methods used for the ChIP-Seq and RNA-Seq analyses are described in detail in Supplemental Methods.

Adox treatment and immunostaining of human and mouse islets. Human islets and islets from GlucagonCre; Rosa26EYFP bigenic mice (27, 28) were cultured, treated with 50 μM adenosine dialdehyde (Adox, A7154; Sigma-Aldrich) for 72 hours, FACS sorted as described before, or prepared for immunostaining.
Immunofluorescent confocal analysis was performed as before (35). Sections were blocked with CAS-Block (00-8120; Invitrogen) and stained using guinea pig anti-insulin (1:500; ab7842, Abcam), rabbit anti-glucagon (1:250; sc13091, Santa Cruz Biotechnology Inc.), guinea-pig anti-Pdx1 (1:1000; gift from C. Wright, Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA), mouse anti–E-cadherin (1:500; 610181, BD Transduction Laboratories), goat anti-GFP (ab6673; Abcam), guinea pig Cy2, guinea pig Cy5, rabbit Cy3, mouse Cy2, mouse Cy5, and goat Cy3 (1:500; Jackson Immunoresearch) antibodies. For quantification of double PDX1 ‘GCC’ cells, Pdx1, glucagon, E-cadherin, and DAPI staining were performed on untreated (control) and Adox-treated islets. All glucagon-positive cells and all PDX1 ‘GCC’ double-positive cells were counted manually (8 slides) for each condition, and the percentage of PDX1 ‘GCC’ double-positive cells of all glucagon-positive cells was calculated.

Statistics. All statistical analyses were performed with the R software package using standard functions. Correlations between genomic samples were assessed using the 2-tailed t test for correlation, implemented in the standard R function cor.test. Wilcoxon signed rank test (standard R function, wilcox.test) was used to assess the significance of gene expression distributions shifted above or below baseline expression. In both cases, significance was defined by the stringent threshold P < 2.2 x 10−16. Additional details of data processing are provided in Supplemental Methods.

Study approval. All animal studies were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

9. Gaulton KJ, et al. A map of open chromatin and goat Cy3 (1:500; Jackson Immunoresearch) antibodies. For quantification of double PDX1 ‘GCC’ cells, Pdx1, glucagon, E-cadherin, and DAPI staining were performed on untreated (control) and Adox-treated islets. All glucagon-positive cells and all PDX1 ‘GCC’ double-positive cells were counted manually (8 slides) for each condition, and the percentage of PDX1 ‘GCC’ double-positive cells of all glucagon-positive cells was calculated.

Received for publication August 23, 2012, and accepted in revised form December 13, 2012.

Address correspondence to: Klaus H. Kaestner, Department of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, 12-126 Translational Research Center, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA. Phone: 215.898.8759; Fax: 215.573.5892; E-mail: kaestner@mail.med.upenn.edu.

Acknowledgments

We thank Catherine Lee May and Ben Stanger for providing GlucagonCre;Rosa26EYFP mice; Kyoung Jae Won for helpful comments; and Alan Fox, Olga Smirnova, Erik Walp, and Jasmine Zhou for technical assistance. The program for provision of human pancreatic islets is supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant U01 DK070430 and by Beckman Research Center/NIDDK/Integrated Islet Distribution Program grant 10028044. Human islets were also provided by the National Disease Research Interchange, with support from NIH grant U42 RR006042. We thank Paul Hallberg and Charles Fletcher for FACS analysis. This work was supported by NIH grants U01DK089529 and R01DK088383 to K.H. Kaestner and U01DK089569 to M. Grompe.